Alternative tumour-specific antigens
The study of tumour-specific antigens (TSAs) as targets for antitumour therapies has
accelerated within the past decade. The most commonly studied class of TSAs are those …
accelerated within the past decade. The most commonly studied class of TSAs are those …
[HTML][HTML] Gastrointestinal cancer classification and prognostication from histology using deep learning: Systematic review
S Kuntz, E Krieghoff-Henning, JN Kather, T Jutzi… - European Journal of …, 2021 - Elsevier
Background Gastrointestinal cancers account for approximately 20% of all cancer diagnoses
and are responsible for 22.5% of cancer deaths worldwide. Artificial intelligence–based …
and are responsible for 22.5% of cancer deaths worldwide. Artificial intelligence–based …
[HTML][HTML] Clinical-grade detection of microsatellite instability in colorectal tumors by deep learning
Background & Aims Microsatellite instability (MSI) and mismatch-repair deficiency (dMMR)
in colorectal tumors are used to select treatment for patients. Deep learning can detect MSI …
in colorectal tumors are used to select treatment for patients. Deep learning can detect MSI …
[HTML][HTML] Microbial community heterogeneity within colorectal neoplasia and its correlation with colorectal carcinogenesis
Background & Aims Gut microbial dysbiosis has pivotal involvement in colorectal cancer
(CRC). However, the intratumoral microbiota and its association with CRC progression …
(CRC). However, the intratumoral microbiota and its association with CRC progression …
Tumor heterogeneity in colorectal cancer: what do we know so far?
X Sagaert, A Vanstapel, S Verbeek - Pathobiology, 2018 - karger.com
Colorectal cancer is not one disease but rather a collection of neoplastic diseases. Due to
heterogeneity in the disease biology, therapy response, and prognosis, extensive disease …
heterogeneity in the disease biology, therapy response, and prognosis, extensive disease …
Intratumor heterogeneity: the hidden barrier to immunotherapy against MSI tumors from the perspective of IFN-γ signaling and tumor-infiltrating lymphocytes
W Wu, Y Liu, S Zeng, Y Han, H Shen - Journal of hematology & oncology, 2021 - Springer
In this era of precision medicine, with the help of biomarkers, immunotherapy has
significantly improved prognosis of many patients with malignant tumor. Deficient mismatch …
significantly improved prognosis of many patients with malignant tumor. Deficient mismatch …
[HTML][HTML] Molecular subtypes of colorectal cancer: An emerging therapeutic opportunity for personalized medicine
Molecular subtypes-based therapies offer new potential framework for desired and precise
outcome in clinical settings. Current treatment strategies in colorectal cancer are largely 'one …
outcome in clinical settings. Current treatment strategies in colorectal cancer are largely 'one …
Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection
R Garcia-Carbonero, R Salazar, I Duran… - … for immunotherapy of …, 2017 - Springer
Abstract Background Enadenotucirev (formerly ColoAd1) is a tumor-selective chimeric
adenovirus with demonstrated preclinical activity. This phase 1 Mechanism of Action study …
adenovirus with demonstrated preclinical activity. This phase 1 Mechanism of Action study …
Tumor-infiltrating lymphocytes in colorectal cancer: the fundamental indication and application on immunotherapy
Z Bai, Y Zhou, Z Ye, J **ong, H Lan… - Frontiers in Immunology, 2022 - frontiersin.org
The clinical success of immunotherapy has revolutionized the treatment of cancer patients,
bringing renewed attention to tumor-infiltrating lymphocytes (TILs) of various cancer types …
bringing renewed attention to tumor-infiltrating lymphocytes (TILs) of various cancer types …
Clinical relevance of colorectal cancer molecular subtypes
N Rodriguez-Salas, G Dominguez, R Barderas… - Critical reviews in …, 2017 - Elsevier
Colorectal cancer (CRC) is characterized by alteration of critical pathways such TP53
inactivation, BRAF, PI3CA mutations, APC inactivation, KRAS, TGF-β, CTNNB mutations …
inactivation, BRAF, PI3CA mutations, APC inactivation, KRAS, TGF-β, CTNNB mutations …